Skip to main content

The Role of Endoscopy in Inflammatory Bowel Disease

  • Chapter
  • First Online:
Advances in Endoscopy in Inflammatory Bowel Disease
  • 1423 Accesses

Abstract

Endoscopic assessment of mucosal lesions has emerged as an important concept of disease activity in inflammatory bowel disease (IBD), and recently mucosal healing has generally been regarded as a therapeutic goal not only in ulcerative colitis (UC) but also in Crohn’s disease (CD). Several pieces of evidence have now accumulated to show that mucosal healing determined by endoscopy can alter the course of IBD, as it is associated with sustained clinical remission, and reduced rates of hospitalization and surgical resection. Generally, clinical activity indices established in IBD are mainly determined based on subjective/objective signs and the results of laboratory tests. However, those indices sometimes lead to discrepancy compared with endoscopic indices. Although endoscopy has been rarely investigated as a predictor of the clinical course of IBD, there is now growing evidence that morphological examination, including endoscopy, may help to identify among IBD patients those who should be treated with more intensive treatments. Furthermore, as demonstrated in a recent study assessing early intervention with combination of biologics and immunomodulators, endoscopy may help to select patients who will obtain the best results with early intervention. This chapter summarizes the role of endoscopy in IBD by introducing several modalities such as colonoscopy, balloon-assisted enteroscopy, and video capsule endoscopy, as well as CT colonography and MR enterography.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Pineton de Chambrun G, Peyrin-Biroulet L, Lémann M, et al. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol. 2010;7:15–29.

    Article  PubMed  Google Scholar 

  2. Carbonnel F, Lavergne A, Lémann M, et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci. 1994;39:1550–7.

    Article  CAS  PubMed  Google Scholar 

  3. Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2010;16:338–46.

    Article  PubMed  Google Scholar 

  4. Hanauer SB, Sandborn WJ, Dallaire C, et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial. Can J Gastroenterol. 2007;21:827–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br Med J. 1954;2:375–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Paoluzi OA, Pica R, Marcheggiano A, et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-ficacy and tolerability in inducing and maintaining remission. Aliment Pharmacol Ther. 2002;16:1751–9.

    Article  CAS  PubMed  Google Scholar 

  7. Wright R, Truelove SR. Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets. Am J Dig Dis. 1966;11:847–57.

    Article  CAS  PubMed  Google Scholar 

  8. Daperno M, Sostegni R, Scaglione N, et al. Outcome of a conservative approach in severe ulcerative colitis. Dig Liver Dis. 2004;36:21–8.

    Article  CAS  PubMed  Google Scholar 

  9. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterology. 1990;98:811–8.

    Article  CAS  PubMed  Google Scholar 

  10. Nahon S, Bouhnik Y, Lavergne-Slove A, et al. Colonoscopy accurately predicts the anatomical severity of colonic Crohn's disease attacks: correlation with findings from colectomy specimens. Am J Gastroenterol. 2002;97:3102–7.

    Article  PubMed  Google Scholar 

  11. Allez M, Lemann M, Bonnet J, et al. Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol. 2002;97:947–53.

    PubMed  Google Scholar 

  12. Mantzaris GJ, Christidou A, Sfakianakis M, et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. Inflamm Bowel Dis. 2009;15:375–82.

    Article  PubMed  Google Scholar 

  13. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006;63:433–42.

    Article  PubMed  Google Scholar 

  14. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008;371:660–7.

    Article  PubMed  Google Scholar 

  15. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990;99:956–63.

    Article  CAS  PubMed  Google Scholar 

  16. Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology. 2009;136:441–50.

    Article  CAS  PubMed  Google Scholar 

  17. Allez M, Lémann M. Role of endoscopy in predicting the disease course in inflammatory bowel disease. World J Gastroenterol. 2010;16:2626–32.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Hanauer SB. Positioning biologic agents in the treatment of Crohn's disease. Inflamm Bowel Dis. 2009;15:1570–82.

    Article  PubMed  Google Scholar 

  19. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383–95.

    Article  CAS  PubMed  Google Scholar 

  20. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology. 2010;138:463–8.

    Article  PubMed  Google Scholar 

  21. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005;100:2478–85.

    Article  CAS  PubMed  Google Scholar 

  22. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–76.

    Article  CAS  PubMed  Google Scholar 

  23. Ferrante M, Vermeire S, Fidder H, et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis. 2008;2:219–25.

    Article  PubMed  Google Scholar 

  24. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009;137:1250–60.

    Article  CAS  PubMed  Google Scholar 

  25. Carbonnel F, Gargouri D, Lémann M, et al. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther. 2000;14:273–9.

    Article  CAS  PubMed  Google Scholar 

  26. Kobayashi T, Naganuma M, Okamoto S, et al. Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine A treatment for ulcerative colitis. J Gastroenterol. 2010;45:1129–37.

    Article  PubMed  Google Scholar 

  27. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut. 1989;30:983–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Rutgeerts P, Vermeire S, Van Assche G. What is the role of endoscopy in predicting Crohn's disease relapse or course? Inflamm Bowel Dis. 2008;14(Suppl 2):S183–4.

    Article  PubMed  Google Scholar 

  29. van Assche G, Vermeire S, Rutgeerts P. Mucosal healing and anti TNFs in IBD. Curr Drug Targets. 2010;11:227–33.

    Article  PubMed  Google Scholar 

  30. D'Haens G, Geboes K, Ponette E, et al. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology. 1997;112:1475–81.

    Article  PubMed  Google Scholar 

  31. Baert FJ, D'Haens GR, Peeters M, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology. 1999;116:22–8.

    Article  CAS  PubMed  Google Scholar 

  32. Lémann M, Mary JY, Colombel JF, et al. A randomized, doubleblind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology. 2005;128:1812–8.

    Article  PubMed  Google Scholar 

  33. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–9.

    Article  CAS  PubMed  Google Scholar 

  34. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis. 2009;15:1295–301.

    Article  PubMed  Google Scholar 

  35. Rutgeerts P, Van Assche G. What is the role of endoscopy in the postoperative management of Crohn’s disease? Inflamm Bowel Dis. 2008;14(Suppl 2):S179–80.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Haruhiko Ogata .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Japan

About this chapter

Cite this chapter

Ogata, H. (2018). The Role of Endoscopy in Inflammatory Bowel Disease. In: Hibi, T., Hisamatsu, T., Kobayashi, T. (eds) Advances in Endoscopy in Inflammatory Bowel Disease. Springer, Tokyo. https://doi.org/10.1007/978-4-431-56018-0_1

Download citation

  • DOI: https://doi.org/10.1007/978-4-431-56018-0_1

  • Published:

  • Publisher Name: Springer, Tokyo

  • Print ISBN: 978-4-431-56016-6

  • Online ISBN: 978-4-431-56018-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics